/
CRDL
$1.03-$0.01 (-0.96%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$119.9M
115M shares
52-week range
$0.88 – $1.71
18% from low
Exchange
NASDAQ
CS
Borrow rate
1.28%
Moderate
Price (6 mo)
Loading chart…
Change$-1.36
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $62.3K | $0 | $0 | $0 | $0 |
| Cost of revenue | $91.5K | $116.1K | $180.2K | $174.3K | $162.2K | $187.4K | $0 | $0 |
| Gross profit | −$91.5K | −$116.1K | −$180.2K | −$112.0K | −$162.2K | −$187.4K | $0 | $0 |
| Gross margin | — | — | — | -179.9% | — | — | — | — |
| R&D | $1.5M | $2.7M | $8.3M | $8.6M | $14.0M | $10.7M | $14.0M | $14.0M |
| Operating income | −$7.4M | −$10.9M | −$16.2M | −$30.6M | −$30.5M | −$22.5M | −$40.3M | −$34.3M |
| EBITDA | −$7.3M | −$10.4M | −$16.0M | −$24.8M | −$22.7M | −$21.0M | −$36.5M | −$33.7M |
| Net income | −$15.9M | −$10.6M | −$16.2M | −$25.0M | −$22.8M | −$21.2M | −$36.7M | −$33.8M |
| Net margin | — | — | — | -40170.9% | — | — | — | — |
| EPS (diluted) | -0.66 | -0.53 | -0.69 | -0.73 | -0.49 | -0.44 | -0.51 | -0.39 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-0.47 | $-0.55–$-0.38 | 3 |
| 2027 | $3M | $-0.22 | $-0.22–$-0.22 | 2 |
| 2028 | $52M | $0.05 | $-0.28–$0.52 | 3 |
| 2029 | $0 | $0.32 | $0.32–$0.32 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.17
Price
$1.03
Implied downside
-83%
Peer comparison
Cardiol Therapeutics Inc. Class A Common Shares
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
www.cardiolrx.com- Employees
- 18
- IPO / List date
- Jan 15, 2019
Held by traders on TradeandTell
No one on the platform currently holds CRDL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 229,806 | $310.2K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CRDL yet.
